NVS Novartis AG

95.92
+0.39  (+0%)
Previous Close 95.54
Open 96.23
Price To Book 4.14
Market Cap 217,231,755,000
Shares 2,264,600,000
Volume 2,552,043
Short Ratio 2.1
Av. Daily Volume 1,621,817
Stock charts supplied by TradingView

NewsSee all news

  1. Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

    Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal

  2. Novartis completes tender offer for all outstanding shares of The Medicines Company

    Basel, January 6, 2020 — Novartis AG (NYSE:NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation

  3. Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

    EAST HANOVER, N.J., Dec. 9, 2019 /PRNewswire/ -- Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct

  4. Novartis tender offer for The Medicines Company commences

    Basel, December 5, 2019 — Novartis AG (NYSE:NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer

  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Phase 3 data due 2H 2020.
Lu-PSMA-617
Metastatic castration-resistant prostate cancer (mCRPC)
Approval announced May 11, 2018.
Fingolimod
Multiple Sclerosis (MS)
Phase 1 data at AAN May 5, 2019 noted motor function gains.
Zolgensma AVXS-101 STRONG
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 overall survival data due 2H 2020.
Kisqali - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
Zykadia
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 final data due 3Q 2020.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data met primary endpoint - October 16, 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
RELAX-AHF-2 (RLX030)
Acute heart failure
FDA Approval announced October 8, 2019.
RTH258 (brolucizumab)
Wet age-related macular degeneration (AMD)
Phase 3 trial did not meet primary endpoint - December 16, 2019.
QAW039 (fevipiprant) - LUSTER-1
Asthma
Phase 3 trial met primary endpoint - November 8, 2017.
LEE011: MONALEESA-7
Breast cancer - (pre-menopausal)
Phase 3 data met endpoints - August 30, 2019. Data presented at ECTRIMS September 13, 2019 noted reduction in annualized relapse rate (ARR) by 50.5% and 58.8% compared to Aubagio.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ESMO 2019 noted HR=0.724.
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 trial did not meet primary endpoint - July 29, 2019.
Entresto - PARAGON-HF
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 interim analysis 1Q 2020 with full data due in 2021.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Approval announced May 17, 2018.
Erenumab
Migraine
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
LEE011
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Adalimumab
Rheumatoid Arthritis
Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
Inclisiran - ORION-9
Hypercholesterolemia
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Lutathera
Inoperable progressive midgut NETs
FDA Approval announced May 24, 2019.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 1
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 data May 5, 2019 noted 11/22 patients who could sit without support for at least 30 seconds. To be completed in 2021.
Zolgensma AVXS-101 STR1VE EU
Spinal muscular atrophy (SMA) Type 1
Phase 2 trial to be completed 1H 2020.
LJN452
Non-alcoholic steatohepatitis (NASH)
NDA filing due 2019. Moved to 1Q 2020 due to no update.
INC280 - capmatinib
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
LIK066
Obesity
FDA Approval announced May 24, 2019.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
Cosentyx
Psoriasis
Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Completion 2021.
Zolgensma AVXS-101 SPRINT
Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
FDA approval announced March 26, 2019.
Mayzent (siponimod/BAF312)
Secondary progressive multiple sclerosis
Phase 3 trial to be completed 3Q 2020.
PDR001
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
FDA Approval announced November 15, 2019.
Crizanlizumab
Sickle cell disease
Phase 3 trial completed 1Q 2019.
Entresto - PARALLEL-HF
Heart failure
Phase 3 trial met primary endpoint - September 17, 2019.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
FDA Approval announced February 13, 2019.
Egaten
Fascioliasis
FDA Approval announced November 5, 2019.
Biosimilar pegfilgrastim
Pegfilgrastim biosimilar
Phase 3 trial to be completed 2022.
Entresto - PERSPECTIVE
Heart failure
Phase 3 trial to be completed 2H 2021.
Entresto - Panorama
Heart failure
Phase 3 trial met primary endpoint.
QMF149
Asthma
Phase 2/3 trial discontinued due to lack of efficacy.
CNP520
Alzheimer’s Disease
Phase 3 data did not meet primary endpoint - noted October 22, 2019.
QAW039 (fevipiprant) - ZEAL
Asthma
Phase 3 data did not meet primary endpoint - October 31, 2019.
Cosentyx
Psoriatic arthritis
Phase 3 data due 2H 2020.
ABL001
Chronic myeloid leukemia
Phase 3 data due 2H 2020.
Brolucizumab
Diabetic macular edema (DME)
Phase 2 data due 1H 2020.
UNR844
Presbyopia

Latest News

  1. Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

    Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal

  2. Novartis completes tender offer for all outstanding shares of The Medicines Company

    Basel, January 6, 2020 — Novartis AG (NYSE:NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation

  3. Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

    EAST HANOVER, N.J., Dec. 9, 2019 /PRNewswire/ -- Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct

  4. Novartis tender offer for The Medicines Company commences

    Basel, December 5, 2019 — Novartis AG (NYSE:NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer

  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  6. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  7. ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from allegations that Novartis may have issued

  8. ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from

  9. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  10. EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from